CITIC Securities: The Chinese innovative pharmaceutical industry is expected to receive validation and value enhancement of pipeline potential.

According to China Securities Research Report, the schedule for the 2026 ASCO Annual Meeting was officially announced on April 21st and will be held from May 29th to June 2nd in Chicago, USA. As one of the most important oncology academic events globally, many multinational corporations and innovative drug companies from home and abroad will have intensive data releases. Among them, the number of research studies from China has reached a new high: a total of 94 original research results have been selected for oral presentations, indicating that the Chinese innovative drug industry is accelerating towards the forefront of international innovation research and development. China Securities believes that around key events such as the release of ASCO abstracts and data presentations, the Chinese innovative drug industry is expected to validate pipeline potential and increase in value. In conclusion, China Securities maintains a rating of "stronger than the overall market" for the innovative drug industry, and recommends focusing on Chinese innovative drug companies with significant data releases in the field of oncology treatment SOC.